Mabwell (Shanghai) Bioscience Co., Ltd. has issued a proxy circular convening its 2026 fourth Extraordinary General Meeting (EGM), to be held on 17 September 2026 at 15:00 (Hong Kong time) in Shanghai. Shareholders will deliberate on three resolutions—two ordinary and one special—dealing with strategic cooperation and corporate governance adjustments.
Key agenda items
1. Licence Agreement with SynuSight (Ordinary Resolution) • Proposal seeks shareholder approval for Mabwell to enter into a licence arrangement with SynuSight, constituting a related-party transaction. • Specific commercial terms were not detailed in the proxy form; approval would authorise the Board to finalise execution.
2. Joint Science & Technology Project with SynuSight (Ordinary Resolution) • Mabwell plans to collaborate with SynuSight on a scientific research project, also classified as a related-party transaction. • Board authorisation is requested for joint application and subsequent project management.
3. Change in Business Scope and Articles Amendment (Special Resolution) • Management proposes revising the company’s business scope, amending the Articles of Association accordingly, and completing related industrial and commercial registration changes. • Passage requires a two-thirds majority of votes cast by shareholders or their proxies.
Meeting logistics
• Date & Time: Thursday, 17 September 2026, 15:00 (Hong Kong time). • Venue: Conference Room 103, Building 3, Chuangxiang Park, No. 576 Libing Road, Pudong New Area, Shanghai. • Proxy Submission Deadline: Completed forms must reach Tricor Investor Services Limited (17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong) by 15:00 on 16 September 2026. • Shareholders may appoint one or more individual proxies; failing explicit instructions, proxies may vote at their discretion. • Personal attendance supersedes any submitted proxy.
Context
All three proposals focus on expanding Mabwell’s collaboration with SynuSight and realigning corporate objectives. The special resolution’s emphasis on business-scope expansion suggests preparatory steps for broader operational activities, while the ordinary resolutions formalise strategic R&D partnerships. Approval outcomes will shape Mabwell’s trajectory in the upcoming fiscal periods.